Drug intelligence / Profile preview

XBH102

Development stage: Preclinical
Lead developer: GV20 Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

XBH102 is an antibody-drug conjugate (ADC) being developed by GV20 Oncotherapy for the treatment of gastrointestinal (GI) tumors. The drug was identified using GV20's proprietary platform that combines high-throughput functional genomics with artificial intelligence to discover novel cancer targets. XBH102 is designed to deliver a cytotoxic payload directly to tumor cells expressing a specific, though currently undisclosed, antigen associated with GI malignancies. By targeting cancer cells specifically, the therapy aims to enhance efficacy while reducing systemic toxicity. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on XBH102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XBH102.

Explore the full profile